Royalty Pharma plc Class A Ordinary Shares vs Energy Select Sector SPDR Fund — how do they compare? Royalty Pharma plc Class A Ordinary Shares trades at $56.88 (market cap $25.27B), while Energy Select Sector SPDR Fund trades at $65.14 (market cap $40.84B). The key difference: Energy Select Sector SPDR Fund is the larger of the two by market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Energy Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Royalty Pharma plc Class A Ordinary Shares for 1 Days and Energy Select Sector SPDR Fund for 67 Days on average.
| RPRX | XLE | |
|---|---|---|
Market Cap | $25.27B | $40.84B |
Volume | 3,671,183 | 50,409,268 |
Sector | Health | — |
52-Week High | $63.96 | $65.93 |
52-Week Low | $35.44 | $42.61 |
Typical Hold Time | 1 Days | 67 Days |
Enterprise Value | $32.50B | — |
Dividend Yield | 1.66% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XLE trades at $65.09, up 2.7% today amid bullish technical signals from moving averages, though oscillators show caution with RSI levels in overbought territory. The energy ETF faces mixed sentiment as oil prices surge above $100 due to Middle East tensions while futures traders bet on a potential 12% sector decline. Recent news highlights strategic oil reserve concerns and diesel price pressures affecting energy markets.
Outlook remains volatile with geopolitical risks driving short-term gains but fundamental headwinds from potential oil price corrections. Key risks include oil market volatility and Federal Reserve policy impacts, while technical support at $64-$65 provides near-term stability. Investors should weigh high current energy prices against recessionary pressures that could dampen demand.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →